Overview A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus Status: NOT_YET_RECRUITING Trial end date: 2026-06-10 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the efficacy and safety of IMC-002 in the treatment of active SLE.Phase: PHASE1 Details Lead Sponsor: ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.